Sun Pharma Enters Us Derma Space Through Concert Pharma Buy

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Sun Pharma enters US derma space through Concert Pharma buy

ri-calendar-2-lineJan 20, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

India’s biggest pharmaceutical player, Sun Pharma, has signed a definitive agreement to acquire the NASDAQ listed biotechnology company, Concert Pharmaceuticals Inc for $576 million. Concert Pharma boasts of an extensive patent portfolio, with one of its flagship products being deuruxolitinib, an oral drug to treat alopecia areata (an autoimmune dermatological disease attacking hair follicles, resulting in hair loss throughout the body).  

 

The deal is will be undertaken through an upfront cash purchase of all Concert outstanding shares, at $8 per share of common stock. However, additional milestone payments of up to $327 million are payable upon deuruxolitinib crossing the sales milestones of $100 million within a stipulated period. That takes the total consideration to around $827 million overall.


Today, there are limited options at people’s disposal for the treatment of this disease, and one of Sun Pharma’s main focuses is to build a franchise that can serve as therapy centre for such patients. In addition, the drug is in its final stage of testing, and acquiring Concert at this time will ensure a late-stage, best-in-class treatment for the disease.

 

Given that the drug meets its sales targets, shareholders will subsequently receive a bonus of $1 per share. The deal is part of the aggressive inorganic growth plans of Sun Pharm and it broadly gels into its plans of dominating the dermatological segment, where it already has a lead in the US markets.

 

Source: Multiple News Websites

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions